Twist Bioscience Achieves Remarkable Increase in Q3 Income
Transformative Growth at Twist Bioscience
Imagine a biotech company flipping its financial situation from a loss to profit in a mere year. Twist Bioscience Corporation (NASDAQ: TWST) has achieved just that in its latest reporting, showcasing an impressive turnaround with third-quarter income that surpassed analysts' expectations.
Remarkable Financial Results
In the recent quarter, Twist Bioscience posted an income of 33 cents per share, a striking improvement from a loss of $1.47 per share recorded last year. Analysts had anticipated a loss of 55 cents, making this performance all the more notable.
Sales Surge and Net Income Growth
The company reported a substantial net income of $20.39 million, bolstered by a gain of $48.85 million from the sale of part of its business, which equates to an effective contribution of 80 cents per share to their earnings. On an adjusted basis, the loss stood at 47 cents per share, exclusive of the aforementioned gain.
A Look at Revenue Figures
Sales figures also reflected a healthy growth, climbing to $96.057 million compared to $81.45 million last year. This figure not only exceeded the expected consensus of $95.47 million but also laid within the management's guidance of $94 million to $97 million, displaying the company's ability to fulfill market demand effectively.
Customer Engagement and Product Shipments
Twist Bioscience expanded its customer base significantly, serving approximately 2,484 clients in the third quarter, increasing from about 2,300 a year earlier. The company shipped around 237,000 genes, up from approximately 212,000, indicating growing market adoption of its products.
Improving Gross Margins
The gross margin for the quarter improved to 53.4%, up from 43.3% in the previous year, reflecting more efficient operations and increased sales. Such improvements in margins highlight the company's commitment to enhancing its financial health.
Adjusted EBITDA Performance
Twist reported an adjusted EBITDA loss of $(8.0) million for this quarter, a reduction from a loss of $(22.0) million during the same period last year. This reduction signals the potential for future profitability as the company continues its optimization efforts.
Sales Guidance for 2025
Looking ahead, Twist Bioscience has adjusted its fiscal year 2025 sales guidance from $372 million - $379 million to a new range of $374 million - $376 million, slightly above the consensus of $376.21 million. This revised outlook shows the company's confidence in maintaining momentum in its growth trajectory.
Revenue Forecasts from Key Segments
The breakdown of their projected revenue includes expectations of approximately $144 million – $145 million from SynBio, a growth of 16% – 17%; NGS revenue is anticipated at $207 million – $208 million, which reflects a growth of 22% – 23%; and Biopharma is expected to generate around $23 million, representing a growth of 5% – 13%.
Projected Gross Margins and EBITDA
The company forecasts a gross margin of about 50.5% to 51.0% for the fiscal year 2025, with hopes for quarterly sequential improvements. Adjusted EBITDA is anticipated to fall between $(45.0) million to $(47.0) million, also an encouraging shift from previous estimates.
Fourth Quarter Expectations
For the upcoming fourth quarter of fiscal 2025, revenue from Twist is projected to fall in the range of $96 million - $98 million, slightly below the consensus of $99.17 million. The anticipated breakdown includes approximately $38 million-$39 million from SynBio, $52 million-$53 million from NGS, and about $6 million from Biopharma.
Future Outlook
Twist Bioscience remains optimistic, expecting to achieve adjusted EBITDA breakeven by the end of fiscal 2026, showcasing their ambition for long-term sustainability and financial health.
Stock Performance Update
In terms of stock performance, shares of Twist Bioscience experienced a decline of 11.13%, trading at $29.93 at the time of this report. This fluctuation reflects broader market trends and investor sentiment amid volatile market conditions.
Frequently Asked Questions
What is the recent income report for Twist Bioscience?
Twist Bioscience reported a third-quarter income of 33 cents per share, a significant improvement from a loss of $1.47 a year prior.
How has Twist's sales performance changed this quarter?
Sales surged to $96.057 million, exceeding analyst expectations and showcasing the company's strong growth trajectory.
What does the future guidance look like for Twist Bioscience?
The guidance for fiscal year 2025 sales has been revised to a range of $374 million to $376 million, slightly above market expectations.
What were the gross margins for this quarter?
The gross margin for the third quarter increased to 53.4%, showing significant enhancements in operational efficiency.
What are the forecasts for the fourth quarter of 2025?
Twist anticipates fourth-quarter sales between $96 million and $98 million, with revenue growth across key segments expected.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
